CY1107698T1 - Ανασυνδυασμενος φορεας που εκφραζει πολλαπλα συνδιεργερτικα μορια και οι χρησεις του - Google Patents
Ανασυνδυασμενος φορεας που εκφραζει πολλαπλα συνδιεργερτικα μορια και οι χρησεις τουInfo
- Publication number
- CY1107698T1 CY1107698T1 CY20071100941T CY071100941T CY1107698T1 CY 1107698 T1 CY1107698 T1 CY 1107698T1 CY 20071100941 T CY20071100941 T CY 20071100941T CY 071100941 T CY071100941 T CY 071100941T CY 1107698 T1 CY1107698 T1 CY 1107698T1
- Authority
- CY
- Cyprus
- Prior art keywords
- stimulatory
- stimulatory molecules
- recombinant vector
- recombinant
- vectors
- Prior art date
Links
- 230000002452 interceptive effect Effects 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 6
- 230000006044 T cell activation Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000004988 splenocyte Anatomy 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Η παρούσα εφεύρεση είναι ένας ανασυνδυασμένος φορέας που κωδικοποιεί και εκφράζει τουλάχιστον τρία ή περισσότερα συνδιεγερτικά μόρια. Ο ανασυνδυασμένος φορέας μπορεί επιπλέον να περιέχει ένα γονίδιο που κωδικοποιεί ένα ή περισσότερα αντιγόνα-στόχους ή άνοσο επίτοπο αυτών. Αποδεικνύεται η συνεργιστική επίδραση αυτών των συνδιεγερτικών μορίων στην αυξημένη ενεργοποίηση Τ-λεμφοκυττάρων. Ο βαθμός της ενεργοποίησης Τ-λεμφοκυττάρων, χρησιμοποιώντας ανασυνδυασμένους φορείς που περιέχουν γονίδια που κωδικοποιούν τρία συνδιεγερτικά μόρια, ήταν κατά πολυ μεγαλύτερος από το άθροισμα των παρασκευασμάτων ανασυνδυασμένου φορέα που περιέχουν ένα συνδιεγερτικό μόριο και μεγαλύτερη από τη χρήση δύο συνδιεγερτικών μορίων. Τα αποτελέσματα της εφαρμογής των τριπλών συνδιεγερτικών φορέων ήταν περισσότερο δραματικά υπό συνθήκες είτε χαμηλών επιπέδων πρώτου σήματος ή χαμηλών αναλογιών διεγέρτη προς Τ-λεμφοκύτταρα. Αυτό το φαινόμενο παρατηρήθηκε τόσο με τα απομονωμένα CD4+ όσο και με τα CD8+ Τ-λεμφοκύτταρα. Οι ανασυνδυασμένοι φορείς της παρούσας εφεύρεσης είναι χρήσιμοι ως ανοσογόνα και εμβόλια ενάντια στον καρκίνο και σε παθογόνους μικροοργανισμούς και στο να παρέχουν σε κύτταρα ξενιστή, συμπεριλαμβανομένων των δενδριτικών κυττάρων και σπληνο-κυττάρων, ενισχυμένες λειτουργίες που παρουσιάζουν αντιγόνο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11158298P | 1998-12-09 | 1998-12-09 | |
EP99958951A EP1137792B9 (en) | 1998-12-09 | 1999-11-12 | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107698T1 true CY1107698T1 (el) | 2013-04-18 |
Family
ID=22339329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100941T CY1107698T1 (el) | 1998-12-09 | 2007-07-13 | Ανασυνδυασμενος φορεας που εκφραζει πολλαπλα συνδιεργερτικα μορια και οι χρησεις του |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1137792B9 (el) |
JP (2) | JP4409097B2 (el) |
AT (1) | ATE361988T1 (el) |
AU (1) | AU774076C (el) |
CA (2) | CA2678259C (el) |
CY (1) | CY1107698T1 (el) |
DE (1) | DE69936061T2 (el) |
DK (1) | DK1137792T3 (el) |
ES (1) | ES2286902T3 (el) |
PT (1) | PT1137792E (el) |
WO (1) | WO2000034494A1 (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756038B1 (en) * | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
DE10048710A1 (de) * | 1999-09-27 | 2001-10-04 | Gabriele Pecher | Pharmazeutische Zusammensetzung zur Behandlung und Prophylaxe von humanen Tumoren, die das Tumorantigen Muzin und/oder das Carcinoembryonale Antigen (CEA) exprimieren und ihre Verwendung |
AU1013601A (en) * | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US7179462B2 (en) | 2000-06-02 | 2007-02-20 | University Of Connecticut Health Center | α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof |
US7186515B1 (en) | 2000-06-02 | 2007-03-06 | University Of Connecticut Health Center | Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
AU2001288682A1 (en) | 2000-08-30 | 2002-03-13 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
WO2002027007A2 (en) | 2000-09-25 | 2002-04-04 | Regents Of The University Of Michigan | Production of viral vectors |
EP1364037A4 (en) | 2001-02-02 | 2005-08-03 | Chemocentryx Inc | METHODS AND COMPOSITIONS USEFUL IN STIMULATING AN IMMUNE RESPONSE |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US7414032B2 (en) | 2001-06-25 | 2008-08-19 | Immunofrontier, Inc. | Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL |
AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
KR101141951B1 (ko) * | 2003-09-05 | 2012-05-04 | 테리온 바이오로직스, 인크. | 흑색종용 다중-항원 벡터 |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
CA2545164C (en) * | 2003-11-12 | 2016-11-29 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant vectors expressing mucin and carcinoembryoinic antigen |
JP5285855B2 (ja) | 2003-11-12 | 2013-09-11 | アメリカ合衆国 | 膵癌を処置および予防するためのカスタムベクター |
US20090156519A1 (en) * | 2003-12-23 | 2009-06-18 | Aventis Pasteur, Inc. | Modified KSA and Uses Thereof |
US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
KR100790646B1 (ko) * | 2004-07-03 | 2008-01-02 | 재단법인 목암생명공학연구소 | 세포매개 면역반응을 효과적으로 유도하는 hcv수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도 |
ES2313807B1 (es) * | 2005-07-30 | 2009-12-23 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis. |
EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
EP3061462B1 (en) | 2007-07-02 | 2019-02-27 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
CA2702586C (en) * | 2007-10-18 | 2017-08-01 | Bn Immunotherapeutics Inc. | Use of mva to treat prostate cancer |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
JP5588990B2 (ja) * | 2008-10-31 | 2014-09-10 | トレムアールエックス, インコーポレイテッド | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
EP3320915A1 (en) | 2009-04-17 | 2018-05-16 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
AU2012296425B2 (en) | 2011-08-17 | 2017-07-20 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
EP3007711B1 (en) | 2013-06-14 | 2020-10-21 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
JP6641276B2 (ja) * | 2013-11-28 | 2020-02-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター |
JP5917626B2 (ja) * | 2014-07-28 | 2016-05-18 | トレムアールエックス, インコーポレイテッド | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 |
CN107530383A (zh) | 2015-01-09 | 2018-01-02 | 埃图比克斯公司 | 用于埃博拉病毒疫苗接种的方法和组合物 |
JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
WO2016174200A1 (en) * | 2015-04-30 | 2016-11-03 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a b7 protein |
BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
JP2019508044A (ja) * | 2016-03-18 | 2019-03-28 | ナントセル,インコーポレイテッド | 樹状細胞感染のための多モードベクター |
EP3463440A4 (en) * | 2016-05-27 | 2020-04-15 | Etubics Corporation | NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
WO2020061203A1 (en) | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5738852A (en) * | 1993-04-20 | 1998-04-14 | Solis Therapeutics, Inc. | Methods of enhancing antigen-specific T cell responses |
ATE197765T1 (de) * | 1994-10-03 | 2000-12-15 | Us Gov Health & Human Serv | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
AU731860B2 (en) * | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
-
1999
- 1999-11-12 DE DE69936061T patent/DE69936061T2/de not_active Expired - Lifetime
- 1999-11-12 CA CA2678259A patent/CA2678259C/en not_active Expired - Lifetime
- 1999-11-12 PT PT99958951T patent/PT1137792E/pt unknown
- 1999-11-12 DK DK99958951T patent/DK1137792T3/da active
- 1999-11-12 ES ES99958951T patent/ES2286902T3/es not_active Expired - Lifetime
- 1999-11-12 AT AT99958951T patent/ATE361988T1/de active
- 1999-11-12 AU AU16218/00A patent/AU774076C/en not_active Expired
- 1999-11-12 JP JP2000586927A patent/JP4409097B2/ja not_active Expired - Lifetime
- 1999-11-12 EP EP99958951A patent/EP1137792B9/en not_active Expired - Lifetime
- 1999-11-12 WO PCT/US1999/026866 patent/WO2000034494A1/en active IP Right Grant
- 1999-11-12 CA CA002354024A patent/CA2354024C/en not_active Expired - Lifetime
-
2007
- 2007-07-13 CY CY20071100941T patent/CY1107698T1/el unknown
-
2009
- 2009-08-12 JP JP2009187330A patent/JP5254153B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69936061T2 (de) | 2008-01-17 |
AU774076B2 (en) | 2004-06-17 |
DK1137792T3 (da) | 2007-09-10 |
JP5254153B2 (ja) | 2013-08-07 |
EP1137792B9 (en) | 2007-12-12 |
JP4409097B2 (ja) | 2010-02-03 |
JP2002531133A (ja) | 2002-09-24 |
WO2000034494A1 (en) | 2000-06-15 |
ES2286902T3 (es) | 2007-12-01 |
CA2354024C (en) | 2009-12-22 |
CA2678259C (en) | 2016-10-18 |
CA2354024A1 (en) | 2000-06-15 |
EP1137792A1 (en) | 2001-10-04 |
ATE361988T1 (de) | 2007-06-15 |
DE69936061D1 (de) | 2007-06-21 |
AU1621800A (en) | 2000-06-26 |
PT1137792E (pt) | 2007-08-10 |
JP2009254390A (ja) | 2009-11-05 |
AU774076C (en) | 2005-04-14 |
EP1137792B1 (en) | 2007-05-09 |
CA2678259A1 (en) | 2000-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107698T1 (el) | Ανασυνδυασμενος φορεας που εκφραζει πολλαπλα συνδιεργερτικα μορια και οι χρησεις του | |
CY1120265T1 (el) | Μεθοδος παραγωγης αντισωματος με μεταβλητη περιοχη ανθρωπου και με σταθερη περιοχη τρωκτικου | |
WO1994017192A3 (en) | Lysosomal targeting of immunogens | |
AU3867789A (en) | Recombinant mycobacterial expression vehicles and uses therefor | |
AU3041295A (en) | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity | |
GB9711957D0 (en) | Methods and reagents for vaccination | |
GB2136814B (en) | Dna vectors | |
WO1998002546A3 (en) | Dna immunization against chlamydia infection | |
AU2278497A (en) | Novel non-pyrogenic bacterial strains and use of the same | |
HU9500571D0 (en) | Retro-, inverso-, and retro-inverso synthetic peptide analogues | |
AU3472299A (en) | Rna cancer vaccine and methods for its use | |
ES2093427T3 (es) | Corte dirigido de arn utilizando ribonucleasa p eucariotica y secuencia guia externa. | |
CY1112658T1 (el) | Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d | |
Seidel et al. | A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens | |
EP1135482A4 (en) | CANCER CELL VACCINE | |
DE69739385D1 (de) | Verbesserte impfstoffe | |
UA85365C2 (ru) | Продукт конъюгирования цитокина для использования в противораковой терапии | |
DK0843731T3 (da) | Adenovirusvektorer til genterapi | |
ATE234628T1 (de) | Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen | |
WO1998017814A3 (en) | Gene expression and delivery systems and uses | |
WO2000063406A3 (en) | Adenoviral vectors having nucleic acids encoding immunomodulatory molecules | |
AU4368299A (en) | Self-deleting vectors for cancer therapy | |
ATE214427T1 (de) | Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän | |
CA2254082A1 (en) | Metastatic colorectal cancer vaccine | |
AU3980497A (en) | A vector for polynucleotide vaccines |